



S4 Fig. Kaplan-Meier plots for overall survival in patient subgroups stratified by capmatinib treatment. (A) Kaplan-Meier plots for overall survival in patients with gene copy number (GCN) ≥ 4 or MET exon 14 skipping mutation (*METex14*), stratified by capmatinib treatment (log-rank test, p=0.545). (B) Kaplan-Meier plots for overall survival in patients with GCN ≥ 6 or *METex14*, stratified by capmatinib treatment (log-rank test, p=0.689). (C) Kaplan-Meier plots for overall survival in patients with IHC high expression, stratified by capmatinib treatment (log-rank test, p=0.829). mOS, median overall survival.